Launched an educator program that employs over 860 local teachers
Reached a total of 2000+ FTE and PTE employees
Added 75,000 square feet of clean room manufacturing space
Installed 4 new sterile BFS lines
Nephron steps up to respond to COVID-19, seeking FDA approval to ramp up production
Opened a CLIA-certified Diagnostics Lab and began COVID-19 testing for employees, families and businesses in the Midlands and across South Carolina
Launched production of FDA approved hand sanitizer
Broke ground on a historic $215M expansion, including a vaccine production facility
Announced plans for a Kennedy Innovation Complex
Received FDA approval of an Abbreviated New Drug Application (ANDA) for two new products – 0.9% Sodium Chloride IV Bags, and Ketorolac Tromethamine Injection Vials
With the launch of Nephron Nitrile, a glove manufacturing venture, Nephron begins a $100 million construction project, adding a new 400,000 square-foot facility to its campus of existing facilities and hiring 250 new workers in the process
Continued combating the scourge of the COVID-19 pandemic by producing testing chemicals known as reagents, as well as the test kits themselves
Partnered with Dominion Energy to open the Nephron Clinical Lab–a way to support Midlands-area residents with fast, reliable COVID-19 vaccination and testing services
Developed a new wing of existing Nephron facilities where manufacturers can focus on the creation of life-saving antibiotics and chemotherapy drugs
Announced a new syringe and equipment manufacturing venture, Inject EZ
Partnered with the ISPE Foundation to launch a new internship program, which aims to diversify Nephron’s ever-growing employee base
Nephron 503B launched a new, innovative syringe presentation – the Cyclic Olefin Copolymer (COC) syringe
Owner and CEO Lou Kennedy received a National Manufacturing Icon Award from the National Association of Manufacturers (NAM)
§07
ニュース
13 ARTICLES
Julie Rameas Named 2026 Top Women Leader
Julie Rameas, Chief Procurement Officer at Nephron Pharmaceuticals, was named to The Healthcare Technology Report’s 2026 Top Women Leaders in Biotech and Life Sciences list. She joined Nephron in July 2023 and manages strategic sourcing and procurement for the company’s West Columbia, South Carolina campus. The report highlighted her extensive global procurement experience as a key contribution to Nephron’s operations.
NRx Pharma Gets FDA Approval for Ketamine
NRx Pharmaceuticals received FDA approval for its preservative‑free ketamine on October 30, 2026. The drug will be manufactured at Nephron’s West Columbia, South Carolina campus. The approval was announced in a press release by NRx Pharmaceuticals, Inc. (Nasdaq: NRXP).
Nephron Announces CEO Transition
Nephron announced that Lou Kennedy is departing as CEO and that Haywood Miller has been appointed Interim CEO, effective immediately. The company said it remains focused on its transformation strategy and growth priorities, and enters this next chapter with the support of its secured lenders.
Nephron Pharmaceuticals Recognized in 2025 RXinsider Pharmacy500
Nephron Pharmaceuticals has been named to the 2025 Pharmacy500 list by RxInsider, recognizing its influence in the pharmacy supply chain. This is the second consecutive year the company has received this honor. The recognition highlights the company's commitment to providing access to safe and effective medications.
Nephron Pharmaceuticals announced several key appointments to strengthen its leadership team. The new executives include a Chief Operating Officer and an Executive Vice President of Quality Systems.
Nephron Pharmaceuticals Invests $10M in BFS Capacity
Nephron Pharmaceuticals announced a $10 million investment to expand its BFS manufacturing capacity with a new production line. The first product will be BFS IV bottles to address FDA drug shortages. This expansion will improve efficiency and reduce costs for medication production.
Nephron Pharmaceuticals Recognized in 2024 RXinsider Pharmacy500
Nephron Pharmaceuticals Corporation was recognized in the 2024 RXinsider Pharmacy500 list, which honors the top 500 supply chain companies impacting the U.S. dispensing pharmacy industry. CEO Lou Kennedy expressed pride in the recognition and highlighted the company's commitment to quality, transformation, and trust.
NRx Pharmaceuticals and Nephron Pharmaceuticals Sign Co-Development Agreement
NRx Pharmaceuticals and Nephron Pharmaceuticals agreed to develop an intravenous ketamine product designed to prevent self-injection and abuse. They are targeting a launch in November 2024, pending FDA approval.
Nephron Pharmaceuticals Announces Six Key Executive Hires
Nephron Pharmaceuticals Corporation announced the hiring of six key executives, including roles in accounting, quality, and operations. The company highlighted the industry experience of the new hires and expressed pride in their team expansion.
Nephron raises $350M for growth with BlackRock and PNC
Nephron Pharmaceuticals announced a successful $350 million capital raise, led by BlackRock and PNC, to support its future growth. The funding aims to enhance the company's manufacturing capabilities and expand its impact in the pharmaceutical industry. Nephron is known for creating jobs in South Carolina and providing medications nationwide.